Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.
Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL. Campbell P, et al. Among authors: tandar c. Ther Adv Urol. 2024 Nov 8;16:17562872241293779. doi: 10.1177/17562872241293779. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 39524157 Free PMC article.
Combating medical misinformation and rebuilding trust in the USA.
Tandar CE, Lin JC, Stanford FC. Tandar CE, et al. Lancet Digit Health. 2024 Nov;6(11):e773-e774. doi: 10.1016/S2589-7500(24)00197-3. Epub 2024 Oct 7. Lancet Digit Health. 2024. PMID: 39379267 Free article. No abstract available.
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.
Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U. Narang A, et al. Among authors: tandar c. Kidney Cancer. 2024 Sep 5;8(1):135-142. doi: 10.3233/KCA-240016. eCollection 2024. Kidney Cancer. 2024. PMID: 39263256 Free PMC article.
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: tandar c. Prostate. 2024 Jun;84(9):888-892. doi: 10.1002/pros.24696. Epub 2024 Apr 1. Prostate. 2024. PMID: 38561317
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U. Sayegh N, et al. Among authors: tandar c. Eur Urol Focus. 2023 Jan;9(1):106-109. doi: 10.1016/j.euf.2022.06.015. Epub 2022 Jul 11. Eur Urol Focus. 2023. PMID: 35835693